Refine
Document Type
- Article (8)
- Conference Proceeding (2)
- Postprint (1)
Language
- English (11)
Is part of the Bibliography
- yes (11)
Keywords
- endothelin-converting enzyme (2)
- neutral endopeptidase (2)
- 2k1c renovascular hypertension (1)
- DPP-4 inhibition (1)
- DPP-4 inhibitor (1)
- DPP4 inhibition (1)
- Diabetic nephropathy (1)
- Linagliptin (1)
- Renal failure (1)
- Renin-angiotensin system (1)
- TGF-beta 1 (1)
- albuminuria (1)
- angiotensin receptor blockers (1)
- blood pressure (1)
- cardiac remodeling (1)
- chronic kidney disease (1)
- diabetic control (1)
- diabetic nephropathy (1)
- guanylate cyclase (1)
- linagliptin (1)
- oxidative stress (1)
- proteinuria (1)
- proteomic analysis (1)
- pulmonary hypertension (1)
- renovascular hypertension (1)
- telmisartan (1)
Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner. Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy. Animals were allocated to 1 of 4 groups: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus linagliptin; and 5/6 nephrectomy plus telmisartan. Interstitial fibrosis was significantly decreased by 48% with linagliptin but a non-significant 24% with telmisartan versus placebo. The urine albumin-to-creatinine ratio was significantly decreased by 66% with linagliptin and 92% with telmisartan versus placebo. Blood pressure was significantly lowered by telmisartan, but it was not affected by linagliptin. As shown by mass spectrometry, the number of altered peptide signals for linagliptin in plasma was 552 and 320 in the kidney. For telmisartan, there were 108 peptide changes in plasma and 363 in the kidney versus placebo. Linagliptin up-regulated peptides derived from collagen type I, apolipoprotein C1, and heterogeneous nuclear ribonucleoproteins A2/B1, a potential downstream target of atrial natriuretic peptide, whereas telmisartan up-regulated angiotensin II. A second study was conducted to confirm these findings in 5/6 nephrectomy wild-type and genetically deficient DPP-4 rats treated with linagliptin or placebo. Linagliptin therapy in wild-type rats was as effective as DPP-4 genetic deficiency in terms of albuminuria reduction. Thus, linagliptin showed comparable efficacy to telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy. However, the underlying pathways seem to be different. Copyright (C) 2016, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).